The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Exclusion Criteria

• •Pregnant or nursing (lactating) women.
• •Women of child-bearing potential.
• •Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period.
• •Patients requiring oxygen therapy or who experience oxygen desaturation to \< 80% during cycle exercise on room air.
• •Patients with a Wmax value \< 20 W (as determined by the incremental cycle endurance test) at screening.
• •Patients who have had a respiratory tract infection within 6 weeks prior to screening.
• •Patients with contra-indications of cardiopulmonary exercise testing.
• •Patients with concomitant pulmonary disease.
• •Patients with a history (up to and including the screening visit) of asthma.
• •Patients with diabetes Type I or uncontrolled diabetes Type II.
• •Any patient with lung cancer or a history of lung cancer.
• •Any patient with active cancer or a history of cancer with less than 5 years disease free survival time.
• •Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured at the collection of informed consent visit (Visit 1) or randomization is prolonged.
• •Patients who have been vaccinated with live attenuated vaccines within 30 days prior to screening or during the run-in period.
• •Patients unable to successfully use a dry powder inhaler device, metered dose inhaler (MDI), or perform spirometry measurements.